Skip to main content

Table 1 Clinicopathological data of the EAC-patients included in the study

From: HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma

    HER2 expression P value
Total Negative Positive
a) Demographic and pathological results of the cohort
 SEX female 38 10.5% 34 89.5% 4 10.5% 0.333
male 324 89.5% 284 87.70% 40 12.3%  
 Age group <  65 yrs 195 53.8% 167 85.5% 28 14.5% 0.062
>  65 yrs 167 46.1% 151 90.4% 16 9.6%  
 Tumor stage pT1 33 9.1% 26 80.0% 7 20.0% 0.038
pT2 30 8.3% 28 93.9% 2 6.1%  
pT3 287 79.2% 251 87.7% 35 12.3%  
pT4 11 3.0% 11 100.0% 0 0.0%  
 Lymph node metastasis pN0 138 38.0% 113 82.5% 24 17.5% 0.02
pN+ 224 62.0% 204 91.1% 20 8.9%  
 Grading G1/2 152 61.8% 126 82.9% 26 17.1% 0.009
G3/4 94 38.2% 89 94.7% 5 5.4%  
 UICC I 50 13.8% 39 78.8% 11 21.2% 0.039
II 53 14.6% 47 89.1% 6 10.9%  
III 169 46.7% 147 86.9% 22 13.1%  
IV 89 24.6% 84 94.7% 5 5.3%  
b) Cross-table analysis of the patient cohort
  Hazard ratio 95% confidence interval P value
Lower Upper
 SEX (female vs. male) 1.718 0.977 3.023 0.06
 Age group (<  65 vs. >  65 yrs) 1.194 0.914 1.559 0.193
 pT (pT1/2 vs. pT3/4) 1.331 0.982 1.804 0.065
 pN (pN0 vs. pN+) 0.937 0.77 1.139 0.513
 UICC (Stage I/II vs. III/IV) 1.975 1.559 2.503 0
 HER2 expression (neg. vs. pos.) 0.628 0.401 0.983 0.042